Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc
Bullboard Posts
User Avatar Image
(10)
•••
Comment by tkirk62on Mar 24, 2019 3:18pm
66 Views
Post# 29528956

RE:RE:RE:RE:RE:RE:Aide Memoire to Mystic and Muggy

RE:RE:RE:RE:RE:RE:Aide Memoire to Mystic and MuggyAlways interesting to see how facts are twisted to suit whatever narrative you want. First, Goodman is a coward or missed his chance because he didn't buy Paladin and now everything is too expensive. Goodman is bad because he didn't buy it back. Second, Endo is forecasting reduced revenues, so Goodman is bad because Paladin's reduced revenues means Canada's a bad market to be in.

The same two facts (Goodman didn't buy Paladin, and Paladin expects lower sales in 2019) instead could tell the story that Goodman was smart for not paying too much for Paladin. But most here want to paint Goodman as the bad guy so the dots can't be connected that way.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities